High Shear Stress Alters Gene Regulation in Pulmonary Arterial Hypertension

高剪切应力改变肺动脉高压的基因调控

• 批准号: 10557807
• 负责人: Marlene Rabinovitch
• 金额: $ 73.97万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-28 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10557807
• 关键词: ATAC-seq; Address; Adhesions; Affect; Algorithms; Arteries; BMPR2 gene; Biological Assay; Biomanufacturing; Blood Pressure; Blood Vessels; Blood flow; Cell Communication; Cell Proliferation; Cell physiology; Cells; ChIP-seq; Chromatin; Collaborations; Congenital Heart Defects; DNA; DNA Binding; Data; Deposition; Disease; Distal; Elastin; Elastin Fiber; Endothelial Cells; Endothelium; Enhancers; Exposure to; Family; Fibrin; Functional disorder; Funding; Gel; Gene Expression; Gene Expression Regulation; Genes; Genomics; Heterozygote; Homeostasis; Impairment; Inflammation; Intervention; Knock-out; Left; Link; Lung; MADH3 gene; Maps; Mediating; Mesenchymal; Metabolism; Mus; Muscle Cells; NF-kappa B; Natural regeneration; Nature; Obstruction; Pathology; Patients; Peripheral; Permeability; Physiological; Proteins; Pulmonary Hypertension; Pulmonary Vascular Resistance; Pulmonary artery structure; Reporting; Research Personnel; SWI/SNF Family Complex; Shunt Device; Site; Smooth Muscle Myocytes; Structure; Technology; Tissues; Transgenic Mice; Tube; Tubular formation; Untranslated RNA; Vascular Diseases; Veno-Occlusive Disease; bioprinting; chromatin remodeling; derepression; differential expression; gene function; genetic variant; member; monocyte; mortality; neutrophil; novel; prevent; promoter; pulmonary arterial hypertension; pulmonary artery endothelial cell; recruit; response; right ventricular failure; shear stress; transcription factor; transcriptome sequencing

Pulmonary arterial hypertension (PAH) is a debilitating disease in which occlusion of the peripheral arteries of the lung causes elevation in pulmonary vascular resistance that culminates in right heart failure. In this proposal, we relate the progressive nature of PAH to the impact of high shear stress (HSS) on pulmonary arterial (PA) endothelial (EC) and smooth muscle cell (SMC) gene regulation and function with the view that we might be able to use this mechanistic information to reverse established disease. In response to a previous RFA on ‘integrative omics’, we related PAEC enhancer promoter interactions to differentially expressed genes (DEGs) under physiologic conditions of laminar shear stress (LSS). LSS resulted in differential chromatin accessibility, assessed by ATAC Seq, at sites where the transcription factor KLF4 bound DNA at H3K27ac enhancer sites, as assessed by ChIP Seq. However, we could only relate the LSS enhancers to one third of DEGs on the basis of ‘nearest gene’. By incorporating HiChIP and the Activity by Contact (ABC) algorithm, we were able to relate distal enhancers to 80% of DEGs, including skipped genes and those related to PAH, such as BMPR2. HSS is prevalent when there is established vascular disease narrowing the vascular lumen, or if PAH is initiated by the high pulmonary blood flow and pressure of a congenital heart defect. In our Preliminary Studies, we show that HSS has a major impact on expression of PAEC homeostatic genes such as BMPR2, JAG1, ERG, and ELN; moreover, there is heightened expression of endothelial mesenchymal transition (EndMT) genes, such as SNAI1, and increased PAEC permeability and monocyte adhesion. Our ability to build PA EC-SMC bilayers in fibrin gels allows us to study vascular cell interactions under LSS and HSS. Our overarching hypothesis is that changes in PAEC and PAEC-SMC interaction in response to HSS adversely impact the enhancer landscape, gene regulation and function, and can be reversed to prevent progressive PAH pathology. To investigate this, we propose three Specific Aims. In Specific Aim 1, we characterize perturbations in the enhancer-promoter landscape that account for aberrant gene regulation under HSS in control and PAH PAEC, and we link these features to functional abnormalities in permeability, inflammation and EndMT, and to changes in genes and proteins in the PA tissue of PAH patients. In Specific Aim 2, we biofabricate tubular structures with PAEC lining the lumen and SMC surrounding the EC, to determine how cell-cell interactions impact HSS vs LSS mediated gene regulation and function, including SMC proliferation and elastin fiber formation. In Specific Aim 3, we focus on the pronounced HSS mediated reduction in ERG in control and PAH PAEC, to determine if this feature is necessary and sufficient for the HSS-mediated abnormal PAEC gene expression and function. We determine whether the HSS mediated elevation in miR-96 and the reduction in ERG can be subverted by the miR-96 antagomir, both in PAH cells and in a transgenic mouse with deficient ERG. These studies should provide new avenues for intervention to reverse disease by subverting the root cause of HSS mediated-progressive PAH.

肺动脉高压(PAH)是一种使人衰弱的疾病，在这种疾病中，周围动脉闭塞 肺引起肺血管阻力升高，最终导致右心衰竭。在这份提案中， 我们将PAH的进行性与高切应力(HSS)对肺动脉(PA)的影响联系起来。 内皮细胞(EC)和平滑肌细胞(SMC)基因的调控和功能 利用这种机械性的信息来逆转既定的疾病。回应上一次的RFA关于 组学，我们将PAEC增强子启动子之间的相互作用与差异表达基因(Degs)联系在一起 层流剪应力(LSS)的生理条件。LSS导致染色质可及性不同， 由ATAC Seq评估，在转录因子KLF4与H3K27ac增强子位点的DNA结合的位置，AS 由芯片序列评估。然而，我们只能在以下基础上将LSS增强剂与三分之一的DEG联系起来 “最近的基因”。通过结合HiChIP和Activity by Contact(ABC)算法，我们能够将 80%的DEG的远端增强子，包括跳过的基因和与PAH相关的基因，如BMPR2。HSS是 当已经存在的血管疾病使血管管腔变窄时，或者如果PAH是由 先天性心脏病的高肺血流量和高压力。在我们的初步研究中，我们表明 HSS对PAEC内环境平衡基因BMPR2、JAG1、ERG和ELN的表达有重要影响； 此外，内皮细胞间充质转化(EndMT)基因的表达增强，如 Snai1，增加PAEC通透性和单核细胞黏附。我们在以下领域构建PA EC-SMC双层的能力 纤维蛋白凝胶使我们能够研究LSS和HSS下血管细胞的相互作用。我们最重要的假设是 响应于HSS的PAEC和PAEC-SMC相互作用的变化对增强子格局产生不利影响， 基因的调节和功能，并可以逆转，以防止进行性PAH病理。为了调查此事， 我们提出了三个具体目标。在特定的目标1中，我们描述了增强子-启动子中的扰动 在对照和PAH PAEC中，解释了HSS下异常基因调控的景观，我们将这些联系起来 通透性、炎症和内源性MT功能异常的特征，以及基因和 PAH患者PA组织中的蛋白质。在特定目标2中，我们使用PAEC衬里来丰富管状结构 EC周围的管腔和SMC，以确定细胞-细胞相互作用如何影响HSS与LSS介导的 基因调控和功能，包括SMC增殖和弹性蛋白纤维的形成。在具体目标3中，我们 重点研究对照组和PAH PAEC中明显的HSS介导的ERG减少，以确定这一特征 是HSS介导的PAEC基因异常表达和功能的充要条件。我们决定 MIR-96能否逆转HSS介导的miR-96的升高和ERG的降低 Anagomir，在PAH细胞和ERG缺陷的转基因小鼠中都是如此。这些研究应该提供新的 通过颠覆HSS介导的进行性PAH的根本原因来逆转疾病的干预途径。